G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.

Genetics Institute is a U.S. based biotechnology research and development company. The company developed drugs such as Neumega and Recombinate used in the prevention of severe reductions in the number of blood clotting cells. The company was founded in 1980 by Thomas Maniatis and Mark Ptashne, and started off by operating out of Ptashne’s home. Genetics Institute was acquired by Wyeth in 1992 and operates as part of Wyeth’s research division.

Cytomatrix Pty Ltd., a subsidiary of SK3 Group, Inc., is a company headquartered in Waurn Ponds, Australia, focused on commercial physical and biological research. The firm was acquired by Healthcare of Today, Inc. on July 21, 2010.

RxKinetix, Inc. develops new therapeutic drugs. The company uses proven pharmaceuticals and proprietary polymer-based drug delivery technologies and creates new drugs or enhances existing drugs. It also develops drugs for oral mucositis and other supportive care oncology conditions. RxKinetix was founded in 1996 and is located in Boulder, CO

Axaron Bioscience AG is a German private company located in Heidelberg with domestic subsidiaries. The firm develops biotechnologies.

NeuroVision Pharma GmbH is a private company headquartered in Germany that engages in investing in biomedical and natural sciences.

Nexell Therapeutics, Inc. operates as a biotechnology company whose principal subsidiary, Nexell of California, Inc. (NCI) engages in the development of cell therapy products for the treatment of genetic blood disorders, autoimmune diseases, cancer and regenerative medicine applications. Its lead candidate product in Phase III clinical trials is a proprietary cellular product comprised of CD34+ hematopoietic stem cells (HSC) for treatment of chronic granulomatous disease, a life-threatening hereditary disorder. NCI is also developing dendritic cell vaccines for the treatment of certain cancers. In this program, NCI is applying proprietary technology to isolate dendritic cell precursors, activate them ex vivo and transform them into mature dendritic cells suitable for reinfusion into the patient. The initial candidate vaccine is targeting colon cancer. Also, NCI has a preclinical development program for a companion to the HSC stem cell product that is intended for stabilization and maintenance of donor cells.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Bolder BioTechnology, Inc. is a clinical stage protein therapeutics company dedicated to providing patients with easier to use, safer, and more cost effective treatments for their disease. Most protein pharmaceuticals require frequent, often daily, dosing, typically by injection. There is a large unmet medical need for innovative protein drugs that do not require frequent administration. their products address that need.

The Group's principal activity is to produce pharmaceuticals and chemicals. The operations are carried out through the following divisions: Pharmaceuticals; Bio chemical; Chemicals; Food and Other. Pharmaceuticals include ethical drugs, bulk pharmaceuticals and biological research. Bio chemicals deal with biochemical diagnostic reagents, animal health products, agrochemicals and fertilizers. Chemicals includes solvents, plasticizes and their raw materials, detergent raw materials and specialty chemicals. Food includes alcoholic beverages, alcohol, seasonings, confectionery, baking ingredients and processed foods. Others include wholesale, commodity distribution and installation of facilities.

Cell Pro Inc. is a manufacturer of cell culture products used for viral diagnostics and detection.

Oncogene Science, Inc. provided cancer diagnostics services. The company was founded in 1983 and was headquartered in Uniondale, NY.